ATE489096T1 - Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner - Google Patents

Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner

Info

Publication number
ATE489096T1
ATE489096T1 AT04747335T AT04747335T ATE489096T1 AT E489096 T1 ATE489096 T1 AT E489096T1 AT 04747335 T AT04747335 T AT 04747335T AT 04747335 T AT04747335 T AT 04747335T AT E489096 T1 ATE489096 T1 AT E489096T1
Authority
AT
Austria
Prior art keywords
entericial
analogas
pharmaceutical
chloride channel
channel opener
Prior art date
Application number
AT04747335T
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Application granted granted Critical
Publication of ATE489096T1 publication Critical patent/ATE489096T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT04747335T 2003-07-03 2004-07-05 Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner ATE489096T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48430403P 2003-07-03 2003-07-03
PCT/JP2004/009867 WO2005002588A1 (en) 2003-07-03 2004-07-05 Enteric coated composition comprising prostaglandin analogs as chloride channel opener

Publications (1)

Publication Number Publication Date
ATE489096T1 true ATE489096T1 (de) 2010-12-15

Family

ID=33563976

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04747335T ATE489096T1 (de) 2003-07-03 2004-07-05 Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner

Country Status (6)

Country Link
US (1) US8337891B2 (de)
EP (1) EP1641462B1 (de)
JP (1) JP5294559B2 (de)
AT (1) ATE489096T1 (de)
DE (1) DE602004030245D1 (de)
WO (1) WO2005002588A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI387454B (zh) 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
BRPI0707333B8 (pt) * 2006-01-24 2021-05-25 R Tech Ueno Ltd composição farmacêutica que compreende um composto bicíclico, método de estabilização do composto bicíclico e formulação de cápsula de gelatina mole
CN104983712A (zh) * 2006-01-24 2015-10-21 株式会社·R-技术上野 软明胶胶囊制剂
JP5377970B2 (ja) * 2006-02-28 2013-12-25 スキャンポ・アーゲー 慢性閉塞性肺疾患を処置するための方法および組成物
WO2009104205A1 (en) * 2008-02-20 2009-08-27 Lupin Limited Delayed release formulation of chloride channel activator
JP2011032262A (ja) * 2009-06-30 2011-02-17 Sucampo Ag Ｎｓａｉｄの長期使用のための医薬組成物
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
US20120232043A1 (en) * 2009-09-15 2012-09-13 Cemag Lubiprostone for obstetrical or gynecological applications
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
WO2014007606A1 (en) 2012-07-05 2014-01-09 N.V. Nutricia Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
KR20180058758A (ko) 2015-09-22 2018-06-01 그레이버그 비젼, 인크. 안구 장애의 치료를 위한 화합물 및 조성물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU519132B2 (en) * 1978-01-31 1981-11-12 Kureha Kagaku Kogyo K.K. Prostaglandin-steroid conjugates
DE3041601A1 (de) * 1980-10-31 1982-06-16 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue prostacyclinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPS59155325A (ja) * 1983-02-25 1984-09-04 Kohjin Co Ltd 水系の腸溶性コ−テイング剤の製法
DE3504044A1 (de) * 1985-02-04 1986-08-07 Schering AG, Berlin und Bergkamen, 1000 Berlin 9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
TW249226B (de) 1990-04-04 1995-06-11 Aderk Ueno Kk
JPH05139964A (ja) * 1991-11-14 1993-06-08 Takada Seiyaku Kk 塩酸メキシレチン腸溶性製剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
KR19990036322A (ko) 1996-06-10 1999-05-25 류지 우에노 엔도텔린길항제
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
EP0930296B2 (de) * 1996-09-17 2005-11-02 Asahi Glass Company Ltd. Fluorierte prostaglandinderivate und medikamente
WO1999018968A1 (en) * 1997-10-13 1999-04-22 R-Tech Ueno, Ltd. Portal hypertension inhibitor
JP2000319166A (ja) * 1999-03-10 2000-11-21 Kyowa Hakko Kogyo Co Ltd 腸溶製剤
US6197329B1 (en) * 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
ATE402925T2 (de) * 1999-10-15 2008-08-15 Sucampo Ag Neue zusammensetzung enthaltend eine bicyclische verbindung und ein glycerid
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
JP4786866B2 (ja) * 2001-08-31 2011-10-05 スキャンポ・アーゲー クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
JP4889219B2 (ja) * 2002-12-27 2012-03-07 スキャンポ・アーゲー 腹部不快感の処置のためのプロスタグランジン誘導体
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物

Also Published As

Publication number Publication date
DE602004030245D1 (de) 2011-01-05
US8337891B2 (en) 2012-12-25
WO2005002588A1 (en) 2005-01-13
EP1641462A1 (de) 2006-04-05
JP5294559B2 (ja) 2013-09-18
EP1641462B1 (de) 2010-11-24
US20060240106A1 (en) 2006-10-26
JP2007518674A (ja) 2007-07-12

Similar Documents

Publication Publication Date Title
EA200600620A1 (ru) Набор для ингаляции с ингаляционным порошком, содержащим тиотропий
DE602004030245D1 (de) Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
DK1663206T3 (da) 1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imizadol-2-thion som ikke-sedativ alpha 2A-agonist
CO5590918A2 (es) Formulaciones
NO20074295L (no) Substituerte gamma lactamer som terapeutiske midler
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
EA200500213A1 (ru) Диспергируемые таблетки для орального назначения
IS7481A (is) Epóthílon til gjafar um munn
TW200507838A (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
NO20064808L (no) Orale matrixformuleringer med licarbazepin
EA200501565A1 (ru) Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса
SG144141A1 (en) Semi-solid systems containing azetidine derivatives
ITMI20041822A1 (it) "agente terapeutico utile per il trattamento di neoplasie plasmacellulari"
UY27824A1 (es) Nueva formulación para la administración parenteral de crobenetina.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties